NCT05141318

Evaluation of FROM-16 in ATMP Patients & Families

Completed Last updated 28 April 2023

What this trial tests

trial testing FROM-16 Questionnaire in Family Members in 18 participants. Completed in 31 March 2022.

Timeline

9 December 2021

Primary endpoint
31 March 2022

31 March 2022

Quick facts

Lead sponsor	Swansea University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	18
Start date	9 December 2021
Primary completion	31 March 2022
Estimated completion	31 March 2022
Sites	5 locations across United Kingdom

Drugs / interventions tested

• FROM-16 Questionnaire
• Semi-structured two-part interview

Conditions studied

• Family Members — all drugs for Family Members →
• Cancer — all drugs for Cancer →

Sponsor

Swansea University

Who can join

Eligibility, any sex, with Family Members or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Poor health, and its treatment, has impact beyond the healthcare system into wider society. A person's productivity, taxable earnings, benefit payments and community contribution may all be adversely affected by poor health. Family members living with or caring for a patient may suffer equally, or sometimes more than the patient themselves, but this familial burden has gone largely unrecognised by healthcare systems. The Family-Reported Outcome Measure (FROM-16) is the first generic questionnaire designed to measure the impact of any chronic disease on the quality of life of family members or partners of patients with a health condition. Advance Therapy Medicinal Products (ATMPs) are a novel \& ground-breaking therapeutic approach for curative treatment of disease and/or injury where conventional treatments have been ineffective. Such disease/injury generally has an extremely high impact on the patient's quality of life, and also the quality of life of the patient's family, in particular those family members who take on the role of 'informal carer'. ATMPs usually have very high costs and this can limit their usage, especially in the context of low prevalence disease and publicly-funded healthcare systems, where healthcare providers may be reluctant to take on the cost burden of the ATMP therapy. As a result, there is a particular focus on the 'value' of ATMPs. An important component of value is 'Societal Value', where a treatment leads to societal contributions, and considering Societal Value may justify the high cost of ATMPs despite the relatively few patients cured. In this study, we will validate the FROM-16 for use as one measure of the Societal Value of very high cost, potentially curative treatments such as ATMPs.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Feasibility Study Protocol: Investigating Family Reported Outcome Measures (FROMs) in the Estimation of Societal Value of Advanced Therapy Medicinal Products (ATMPs)
   Brilliant C. · · 2023 · DOI 10.21203/rs.3.rs-2474459/v1
2. Feasibility Study Protocol: Investigating Family Reported Outcome Measures (FROMs) in the Estimation of Societal Value of Advanced Therapeutic Medicinal Products (ATMPs)
   Brilliant C, Finlay A, Salek S, Shah R, et al · · 2022 · DOI 10.21203/rs.3.rs-1474778/v1